|
|
Volumn 374, Issue 5, 2016, Pages 493-494
|
|
The authors reply
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
NIVOLUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TAXOID;
CANCER IMMUNOTHERAPY;
DRUG EFFICACY;
DRUG RESPONSE;
HUMAN;
LETTER;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROPORTIONAL HAZARDS MODEL;
STATISTICAL ANALYSIS;
SURVIVAL TIME;
CARCINOMA, NON-SMALL-CELL LUNG;
FEMALE;
LUNG NEOPLASMS;
MALE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
TAXOIDS;
|
|
EID: 84956927996
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1514790 Document Type: Letter |
|
Times cited : (31)
|
|
References (1)
|
